RGEN: financial statements from SEC — TradeAlmanac

RGEN

Repligen Corporation: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	738m	634m
Cost of revenue	352m	360m
Research and development	54m	43m
Selling, general and administrative	291m	263m
Operating expenses	683m	670m
Operating income	55m	−35m
Pre-tax income	62m	−27m
Income tax	13m	−2m
Net income	49m	−26m
Earnings per share	0.87	−0.46
Earnings per share, diluted	0.86	−0.46
Weighted average shares	56,234	55,937
Weighted average shares, diluted	56,561	55,937

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	583m	566m	749m	709m	697m	757m	784m	809m
Short-term investments	202m	202m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	117m	175m
Depreciation and amortisation	79m	70m
Share-based compensation	33m	48m
Capital expenditure	24m	26m
Investing cash flow	−298m	−86m
Share buybacks	0

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)